Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT-C phase 3 trial of Xeomin for chronic migraine prevention
2024-515682-34-00Phase 3Authorised
- Sponsor
- Merz
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in chronic migraine (3 arms), sponsored by Merz. Primary endpoint: Change in monthly migraine days to Month 6 - Dose A. Planned start Oct 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2024-515682-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515682-34-00.